Due to the reported insufficient therapeutic efficacy of cblb−/− CD8+ T cell ACT alone [21], we employed a combined treatment with a DC vaccine to induce in vivo selection of tumor antigen-specific CD8+ T cells. This evidence concerns the gene CD8A and neoplasm.